Date: 2016-06-10
Type of information: Nomination
Compound:
Company: Amicus Therapeutics (USA - NJ)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On June 10, 2016, Amicus Therapeutics announced the election and appointment of Craig A. Wheeler to its Board of Directors, effective immediately. In addition, Amicus announced that John F. Crowley, Margaret G. McGlynn, Michael G. Raab, and Glenn P. Sblendorio were re-elected at the 2016 Annual Meeting of Stockholders. Craig Wheeler has extensive experience in leading biopharmaceutical companies to advance a wide range of treatments for serious diseases. He is currently President and CEO of Momenta Pharmaceuticals, where he also serves on the board of directors. He led Momenta through the launch of its first complex drug products, including the first generic versions of Lovenox® and once-daily Copaxone®. He has also overseen the company's growth into a diversified business, with a development pipeline of biosimilar biologics as well as novel therapeutics for oncology and autoimmune indications. Prior to Momenta, Craig worked at Chiron Corporation as President, Chiron BioPharmaceuticals (now Novartis Vaccines & Diagnostics). Prior to joining Chiron, Craig was a senior member of The Boston Consulting Group's health care practice. Mr. Wheeler also worked for Merck's MSDRL research unit, where he served as a senior engineer in process development and at Hybritech as a financial analyst. Mr. Wheeler previously served for nine years as the Chairman of the Board of Avanir Pharmaceuticals where he helped oversee the transition of the company from a research-based platform to a fully integrated CNS pharmaceutical company until 2015 when it was acquired by Otsuka Pharmaceuticals for $3.5 billion. He also served as GPhA's Chairman of the Board of Directors from 2014 to February 2016. In 2011 Mr. Wheeler was an E&Y Entrepreneur of the Year Regional Award winner. He holds a BS and an MS degree in chemical engineering from Cornell University, and an MBA from the Wharton School of the University of Pennsylvania.
Financial terms:
Latest news:
